Method and composition for potentiating neuroleptic drugs
AssigneeNelson Research & Development Company
InventorKjell Fuxe
Life of this patent
Estimating the term…
Abstract
A method and composition for potentiating the effects of neuroleptic drugs by administering to a human having a disorder normally treatable with a neuroleptic drug, a neuroleptic drug in combination with a potentiating amount of an amino acid of the formula ##SPC1## Where R is fluorine, chlorine, bromine or trifluoromethyl and their salts.
Claims8
A method for potentiating the neuroleptic activity of butyrophenone derivatives having neuroleptic activity comprising administering to a schizophrenic about 10 to about 50 percent of a conventional dosage amount of a butyrophenone derivative having neuroleptic activity and an amount equal to about 0.1 to about 50 mg/kg of a compound, or a pharmaceutically acceptable salt thereof, having the structural formula ##SPC4##
- wherein R is selected from the group consisting of fluorine, chlorine, bromine and trifluoromethyl.
A method for potentiating the neuroleptic activity of butyrophenone derivatives comprising administering to a schizophrenic about 10 to about 50 percent of a conventional dosage amount of a butyrophenone derivative selected from the group consisting of haloperidol and trifluperidol and an amount equal to about 0.1 to about 10 mg/kg of .beta.-(4-chlorophenyl)-gamma-aminobutyric acid or a pharmaceutically acceptable salt thereof.
A composition in unit dosage form comprising about 10 to about 50 percent of a conventional dosage amount of a butyrophenone derivative having neuroleptic activity and an amount equal to about 0.1 to about 50 mg/kg of a compound or a pharmaceutically acceptable salt thereof having the structural formula ##SPC5##
- wherein R is selected from the group consisting of fluorine, chlorine, bromine and trifluoromethyl.
A composition in unit dosage form comprising about 10 to about 50 percent of a conventional dosage amount of a butyrophenone derivative selected from the group consisting of haloperidol and trifluperidol and an amount equal to about 0.1 to about 10 mg/kg of .beta.-(4-chlorophenyl)-gammaaminobutyric acid or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.